Last updated: February 11, 2025
Sponsor: Children's Cancer Group, China
Overall Status: Active - Recruiting
Phase
4
Condition
Lymphoma
Platelet Disorders
Marginal Zone Lymphoma
Treatment
Combined chemotherapy with or without involved-field radiotherapy
Clinical Study ID
NCT04726501
CCCG-HD-2018
Ages 1-18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Patient must be ages 1 to 18 years at the time of diagnosis; Newly diagnosed,histologically confirmed Hodgkin disease (No nodular lymphocyte-predominant Hodgkinlymphoma)
Exclusion
Exclusion Criteria:
- Patients have received prior cytotoxic chemotherapy for the current diagnosis or anycancer, if any steroid applied, total prior steroids dosage < Prednisone 80 mg/m2;Patients have congenital immunodeficiency, HIV infection, or prior organ transplant;Patients have overwhelming infection, and a life expectancy of < 2 weeks
Study Design
Total Participants: 200
Treatment Group(s): 1
Primary Treatment: Combined chemotherapy with or without involved-field radiotherapy
Phase: 4
Study Start date:
April 01, 2018
Estimated Completion Date:
December 31, 2027
Study Description
Connect with a study center
West China Second University Hospital, Sichuan University, Chengdu, China
Chengdu,
ChinaActive - Recruiting
Nanjing Children's Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Nanjing,
ChinaActive - Recruiting
Shanghai Children's Medical Center
Shanghai, 200127
ChinaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.